<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37612310</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>23</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Persistent symptoms after COVID-19 are not associated with differential SARS-CoV-2 antibody or T cell immunity.</ArticleTitle><Pagination><StartPage>5139</StartPage><MedlinePgn>5139</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">5139</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-023-40460-1</ELocationID><Abstract><AbstractText>Among the unknowns in decoding the pathogenesis of SARS-CoV-2 persistent symptoms in Long Covid is whether there is a contributory role of abnormal immunity during acute infection. It has been proposed that Long Covid is a consequence of either an excessive or inadequate initial immune response. Here, we analyze SARS-CoV-2 humoral and cellular immunity in 86 healthcare workers with laboratory confirmed mild or asymptomatic SARS-CoV-2 infection during the first wave. Symptom questionnaires allow stratification into those with persistent symptoms and those without for comparison. During the period up to 18-weeks post-infection, we observe no difference in antibody responses to spike RBD or nucleoprotein, virus neutralization, or T cell responses. Also, there is no difference in the profile of antibody waning. Analysis at 1-year, after two vaccine doses, comparing those with persistent symptoms to those without, again shows similar SARS-CoV-2 immunity. Thus, quantitative differences in these measured parameters of SARS-CoV-2 adaptive immunity following mild or asymptomatic acute infection are unlikely to have contributed to Long Covid causality. ClinicalTrials.gov (NCT04318314).</AbstractText><CopyrightInformation>&#xa9; 2023. Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Altmann</LastName><ForeName>Daniel M</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0002-2436-6192</Identifier><AffiliationInfo><Affiliation>Department of Immunology and Inflammation, Imperial College London, London, UK. d.altmann@imperial.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Catherine J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joy</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cardiovascular Science, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otter</LastName><ForeName>Ashley D</ForeName><Initials>AD</Initials><Identifier Source="ORCID">0000-0002-8317-9194</Identifier><AffiliationInfo><Affiliation>UK Health Security Agency, Porton Down, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gibbons</LastName><ForeName>Joseph M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-7238-2381</Identifier><AffiliationInfo><Affiliation>Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pade</LastName><ForeName>Corinna</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swadling</LastName><ForeName>Leo</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-0537-6715</Identifier><AffiliationInfo><Affiliation>Division of Infection and Immunity, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maini</LastName><ForeName>Mala K</ForeName><Initials>MK</Initials><Identifier Source="ORCID">0000-0001-6384-1462</Identifier><AffiliationInfo><Affiliation>Division of Infection and Immunity, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>Tim</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-3783-1284</Identifier><AffiliationInfo><Affiliation>UK Health Security Agency, Porton Down, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Semper</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>UK Health Security Agency, Porton Down, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKnight</LastName><ForeName>&#xc1;ine</ForeName><Initials>&#xc1;</Initials><AffiliationInfo><Affiliation>Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noursadeghi</LastName><ForeName>Mahdad</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4774-0853</Identifier><AffiliationInfo><Affiliation>Division of Infection and Immunity, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manisty</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-0245-7090</Identifier><AffiliationInfo><Affiliation>St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cardiovascular Science, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Treibel</LastName><ForeName>Thomas A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cardiovascular Science, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moon</LastName><ForeName>James C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cardiovascular Science, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>COVIDsortium investigators</CollectiveName></Author><Author ValidYN="Y"><LastName>Boyton</LastName><ForeName>Rosemary J</ForeName><Initials>RJ</Initials><Identifier Source="ORCID">0000-0002-5608-0797</Identifier><AffiliationInfo><Affiliation>Department of Infectious Disease, Imperial College London, London, UK. r.boyton@imperial.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lung Division, Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK. r.boyton@imperial.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04318314</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/W020610/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D000068397">Clinical Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058345" MajorTopicYN="N">Asymptomatic Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>R.J.B. and D.M.A. are members of the Global T cell Expert Consortium and have consulted for Oxford Immunotec outside the submitted work. DMA has received honorarium payments from Pfizer, AstraZeneca and Novavax for consultancy work. The remaining authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>24</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>23</Day><Hour>23</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>8</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37612310</ArticleId><ArticleId IdType="pmc">PMC10447583</ArticleId><ArticleId IdType="doi">10.1038/s41467-023-40460-1</ArticleId><ArticleId IdType="pii">10.1038/s41467-023-40460-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19latestinsights/infections#long-covid</Citation></Reference><Reference><Citation>Davis HE, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. doi: 10.1016/j.eclinm.2021.101019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat. Med. 2022;28:1706&#x2013;1714. doi: 10.1038/s41591-022-01909-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01909-w</ArticleId><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Munblit D, et al. A core outcome set for post-COVID-19 condition inadults for use in clinical practice and research: an international Delphi consensus study. Lancet Respir. Med. 2022;10:715&#x2013;724. doi: 10.1016/S2213-2600(22)00169-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00169-2</ArticleId><ArticleId IdType="pmc">PMC9197249</ArticleId><ArticleId IdType="pubmed">35714658</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, et al. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. 2022;399:2263&#x2013;2264. doi: 10.1016/S0140-6736(22)00941-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00941-2</ArticleId><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm#technical_notes</Citation></Reference><Reference><Citation>Altmann DM, Boyton RJ. Decoding the unknowns in Long Covid. BMJ. 2021;372:n132. doi: 10.1136/bmj.n132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n132</ArticleId><ArticleId IdType="pubmed">33541867</ArticleId></ArticleIdList></Reference><Reference><Citation>Callard, F. &amp; Perego, E. How and why patients made long covid. Soc. Sci. Med. 2021268:113426 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7539940</ArticleId><ArticleId IdType="pubmed">33199035</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591:639&#x2013;644. doi: 10.1038/s41586-021-03207-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03207-w</ArticleId><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollner A, et al. Postacute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases. Gastroenterology. 2022;163:495&#x2013;506.e8. doi: 10.1053/j.gastro.2022.04.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2022.04.037</ArticleId><ArticleId IdType="pmc">PMC9057012</ArticleId><ArticleId IdType="pubmed">35508284</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann, D. M., Whettlock, E. M., Liu, S., Arachchillage, D. J. &amp; Boyton, R. J. The immunology of Long COVID. Nat Rev Immunol10.1038/s41577-023-00904-7 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37433988</ArticleId></ArticleIdList></Reference><Reference><Citation>Littlefield KM, et al. SARS-CoV-2-specific T cells associate with inflammation and reduced lung function in pulmonary post-acute sequalae of SARS-CoV-2. PLoS Pathog. 2022;18:e1010359. doi: 10.1371/journal.ppat.1010359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1010359</ArticleId><ArticleId IdType="pmc">PMC9176759</ArticleId><ArticleId IdType="pubmed">35617421</ArticleId></ArticleIdList></Reference><Reference><Citation>Files JK, et al. Duration of post-COVID-19 symptoms is associated with sustained SARS-CoV-2-specific immune responses. JCI Insight. 2021;6:e151544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8410022</ArticleId><ArticleId IdType="pubmed">34143754</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg B, et al. Long COVID in a prospective cohort of home-isolated patients. Nat. Med. 2021;27:1607&#x2013;1613. doi: 10.1038/s41591-021-01433-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01433-3</ArticleId><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin K. et al. Long COVID manifests with T cell dysregulation, inflammation, and an uncoordinated adaptive immune response to SARS-CoV-2. bioRxiv10.1101/2023.02.09.527892 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10834368</ArticleId><ArticleId IdType="pubmed">38212464</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, et al. Long-term SARS-CoV-2-specific immune and inflammatory response in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep. 2021;10:109518. doi: 10.1016/j.celrep.2021.109518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109518</ArticleId><ArticleId IdType="pmc">PMC8342976</ArticleId><ArticleId IdType="pubmed">34358460</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Abell&#xe1;n J, et al. Antibody Response to SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: a Longitudinal Study. J. Clin. Immunol. 2021;41:1490&#x2013;1501. doi: 10.1007/s10875-021-01083-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-021-01083-7</ArticleId><ArticleId IdType="pmc">PMC8285689</ArticleId><ArticleId IdType="pubmed">34273064</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerum TV, et al. Persistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9. Sci. Rep. 2021;11:23205. doi: 10.1038/s41598-021-02547-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-02547-x</ArticleId><ArticleId IdType="pmc">PMC8636497</ArticleId><ArticleId IdType="pubmed">34853380</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds CJ, et al. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science. 2021;372:1418&#x2013;1423. doi: 10.1126/science.abh1282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abh1282</ArticleId><ArticleId IdType="pmc">PMC8168614</ArticleId><ArticleId IdType="pubmed">33931567</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds CJ, et al. Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants. Science. 2022;375:183&#x2013;192. doi: 10.1126/science.abm0811.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm0811</ArticleId><ArticleId IdType="pmc">PMC10186585</ArticleId><ArticleId IdType="pubmed">34855510</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds CJ, et al. Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Science. 2022;377:eabq1841. doi: 10.1126/science.abq1841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abq1841</ArticleId><ArticleId IdType="pmc">PMC9210451</ArticleId><ArticleId IdType="pubmed">35699621</ArticleId></ArticleIdList></Reference><Reference><Citation>Swadling L, et al. Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. Nature. 2022;601:110&#x2013;117. doi: 10.1038/s41586-021-04186-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04186-8</ArticleId><ArticleId IdType="pmc">PMC8732273</ArticleId><ArticleId IdType="pubmed">34758478</ArticleId></ArticleIdList></Reference><Reference><Citation>Captur, G. et al. Plasma proteomic signature predicts who will get persistent symptoms following SARS-CoV-2 infection. EBioMedicine. 104293. 10.1016/j.ebiom.2022.104293. (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9515404</ArticleId><ArticleId IdType="pubmed">36182629</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds CJ, et al. Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. Sci. Immunol. 2020;5:eabf3698. doi: 10.1126/sciimmunol.abf3698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abf3698</ArticleId><ArticleId IdType="pmc">PMC8101131</ArticleId><ArticleId IdType="pubmed">33361161</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Y, et al. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat. Immunol. 2020;21:1336&#x2013;1345. doi: 10.1038/s41590-020-0782-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0782-6</ArticleId><ArticleId IdType="pmc">PMC7611020</ArticleId><ArticleId IdType="pubmed">32887977</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu ED, et al. Development of a T cell-based immunodiagnostic system to effectively distinguish SARS-CoV-2 infection and COVID-19 vaccination status. Cell Host Microbe. 2022;30:388&#x2013;399. doi: 10.1016/j.chom.2022.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2022.02.003</ArticleId><ArticleId IdType="pmc">PMC8824221</ArticleId><ArticleId IdType="pubmed">35172129</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulley ML. Molecular diagnosis of Epstein-Barr virus related diseases. J. Mol. Diag. 2001;3:1&#x2013;10. doi: 10.1016/S1525-1578(10)60642-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1525-1578(10)60642-3</ArticleId><ArticleId IdType="pmc">PMC1907346</ArticleId><ArticleId IdType="pubmed">11227065</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>